These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 17988723)

  • 1. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
    Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
    Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
    Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
    Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
    Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
    Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.
    Connolly DC; Bao R; Nikitin AY; Stephens KC; Poole TW; Hua X; Harris SS; Vanderhyden BC; Hamilton TC
    Cancer Res; 2003 Mar; 63(6):1389-97. PubMed ID: 12649204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a Müllerian-inhibiting substance autocrine/paracrine system in adult human endometrium.
    Wang J; Dicken C; Lustbader JW; Tortoriello DV
    Fertil Steril; 2009 Apr; 91(4):1195-203. PubMed ID: 18328480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
    Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
    Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of cystic glandular hyperplasia of the endometrium in Mullerian inhibitory substance type II receptor-pituitary tumor transforming gene transgenic mice.
    El-Naggar SM; Malik MT; Martin A; Moore JP; Proctor M; Hamid T; Kakar SS
    J Endocrinol; 2007 Jul; 194(1):179-91. PubMed ID: 17592032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haymaker gene expression in malignant and normal gynecologic tissues.
    Borowsky ME; Das B; Axiotis CA; Malka ES; Abulafia O; Norin AJ
    J Histochem Cytochem; 2006 Jul; 54(7):753-61. PubMed ID: 16495475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.
    Rodriguez-Garcia A; Sharma P; Poussin M; Boesteanu AC; Minutolo NG; Gitto SB; Omran DK; Robinson MK; Adams GP; Simpkins F; Powell DJ
    Mol Ther; 2020 Feb; 28(2):548-560. PubMed ID: 31870622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines.
    Dowdy SC; Gostout BS; Shridhar V; Wu X; Smith DI; Podratz KC; Jiang SW
    Gynecol Oncol; 2005 Oct; 99(1):126-34. PubMed ID: 16023706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
    Tassi RA; Bignotti E; Rossi E; Falchetti M; Donzelli C; Calza S; Ravaggi A; Bandiera E; Pecorelli S; Santin AD
    Gynecol Oncol; 2007 Jun; 105(3):578-85. PubMed ID: 17343903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YWK-II protein as a novel G(o)-coupled receptor for Müllerian inhibiting substance in cell survival.
    Yin X; Ouyang S; Xu W; Zhang X; Fok KL; Wong HY; Zhang J; Qiu X; Miao S; Chan HC; Wang L
    J Cell Sci; 2007 May; 120(Pt 9):1521-8. PubMed ID: 17452623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
    Wang P; Wu X; Chen W; Liu J; Wang X
    Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.
    Andrews P; Zhao X; Allen J; Li F; Chang M
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):203-14. PubMed ID: 17447067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer.
    Campos X; Muñoz Y; Selman A; Yazigi R; Moyano L; Weinstein-Oppenheimer C; Lara HE; Romero C
    Gynecol Oncol; 2007 Jan; 104(1):168-75. PubMed ID: 16935322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.
    Salceda S; Tang T; Kmet M; Munteanu A; Ghosh M; Macina R; Liu W; Pilkington G; Papkoff J
    Exp Cell Res; 2005 May; 306(1):128-41. PubMed ID: 15878339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.
    Drapkin R; von Horsten HH; Lin Y; Mok SC; Crum CP; Welch WR; Hecht JL
    Cancer Res; 2005 Mar; 65(6):2162-9. PubMed ID: 15781627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy.
    Bagley RG; Rouleau C; Weber W; Mehraein K; Smale R; Curiel M; Callahan M; Roy A; Boutin P; St Martin T; Nacht M; Teicher BA
    Microvasc Res; 2011 Nov; 82(3):253-62. PubMed ID: 21958527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alteration of early growth response 1 expression in gastroenterological cancers and its biological significance].
    An J; Guo RF; Zhang L; Geng PL; Lü YY
    Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1384-9. PubMed ID: 18953875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
    Sakaguchi J; Kyo S; Kanaya T; Maida Y; Hashimoto M; Nakamura M; Yamada K; Inoue M
    Gynecol Oncol; 2005 Sep; 98(3):427-33. PubMed ID: 15993480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.